LONDON – After more than a decade in clinical development, Pharming Group NV completed the final stage of European approval for its lead product Ruconest, in the treatment of acute attacks of hereditary angioedema (HAE), triggering the payment of a €5 million (US$6.94 million) milestone payment from marketing and distribution partner Swedish Orphan Biomedical AB. (BioWorld International) Read More
